Precision Medicine Software Market Top Players, Segments & Regional Trends By 2034

Straits Research released its highly anticipated report, “Global Precision Medicine Software Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.26 billion in 2025 and is anticipated to grow to USD 6.10 billion by 2034, growing at a CAGR of 11.67% from 2026-2034.

Market Dynamics

The growth of the precision medicine software market is driven by the rapid integration of artificial intelligence and machine learning algorithms that enhance the interpretation of genomic, transcriptomic, and clinical data for personalized therapy selection. The increasing collaboration between technology providers, research institutes, and pharmaceutical companies to develop predictive models and digital companion diagnostics further accelerates adoption. However, the market faces restraints due to limited interoperability and a lack of standardized data formats across healthcare systems, which restricts seamless information exchange and delays large-scale clinical implementation. On the other hand, the expanding integration of precision medicine software with digital therapeutics and remote monitoring platforms presents a major opportunity, enabling real-time tracking of treatment response and supporting adaptive, patient-specific healthcare delivery.

Market Highlights

• Component: Based on Component, software dominated the market with 79.90% share.
• Delivery Mode: Based on the Delivery Mode, the cloud-based segment dominated the market with a 73.40% share.
• Application: Based on Application, the oncology segment dominated the market with a 34.30% share.
• Technology: Based on Technology, AI/machine learning models & generative AI segment dominated the market growth with 38.98%.
• End Use: Based on End Use, the hospitals segment dominated the market in 2025, with a revenue share of 42.34%.
• Regional Insights: North America dominated the market with more than 47% of market share in 2025, driven by the strong presence of genomic research infrastructure, early adoption of AI-based precision healthcare platforms, and extensive collaborations between technology providers, pharmaceutical companies, and healthcare institutions.